CD19 and B-cell chronic lymphocytic leukemia: Importantly, two studies also demonstrated the feasibility of utilizing PI3K blockade to generate CD19 CAR T cells with superior anti-tumor activity in xenograft models of chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL), using T cells derived from CLL patients (54, 57).